Sign in
CTNM Stock Price, Chart, Stats & News
Contineum Therapeutics, Inc. Class A Common Stock
Save
446.39M
Market cap
–
Current P/E
–
Forward P/E
CTNM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.68% |
ROE | -30.08% |
D/E | 0.03x |
Interest coverage ratio | – |
CTNM valuation
P/E | – |
P/S | – |
P/B | 1.58x |
P/CF | -7.44x |
P/FCF | -8.97x |
P/OCF | -7.44x |
PEG | -1.00x |
EV multiple | -8.87x |
About
Contineum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery and advancement of innovative oral small molecule therapies. Their primary focus lies in addressing neurological, inflammatory, and immunological disorders characterized by significant unmet medical needs. The company's foremost therapeutic candidate is PIPE-791, a pioneering, brain-penetrant small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R).
Similar securities
Based on sector and market capitalization
Report issue